This conference uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.
Dan Browne is one of our co-founders and has served as its President and Chief Executive Officer since we commenced operations and completed its first institutional venture financing in 2006 and taking the company public in 2014. Mr. Browne has more than a 25-year career of executive leadership experience across both biopharmaceuticals and medical technologies. Prior to joining Revance, Mr. Browne served as President and Chief Executive Officer of Neomend, Inc., a medical biomaterial company focused on soft tissue repair, Prograft Medical Inc., a medical device company focused on minimally-invasive treatments of cardiovascular and vascular disease, and W.L Gore & Associates where he served in multiple leadership positions across product development, sales and marketing and business development in the Gore Medical Products Division. Over his career, Mr. Browne has developed extensive business, management and leadership experience, as well as extensive knowledge of Revance and its product and global operations.
Peter Guenter is Chief Executive Officer of Almirall SA since October 1st, 2017. He is also member of the board of EFPIA (European Federation of Pharmaceutical Industries and Associations) and member of the board of Galapagos NV, a leading biotechnology company.
He started his career in Smith Kline (now Glaxo Smith Kline) and later worked for Novartis.
He entered in 1995 in the Sanofi Group, where he would spend 22 years of his professional life, in job assignments with increasing responsibilities, amongst others General Manager Belgium, Vice President Eastern and Northern Europe, General Manager Germany, Senior Vice President Europe, Executive Vice President Global Commercial Operations, Executive Vice President General Medicine and Emerging Markets, Executive Vice President Diabetes and Cardiovascular.
He has been member of Sanofi’s Executive Committee from 2013 till 2017.
He holds a Master’s Degree in Physical Education from the Faculty of Medicine and Health Sciences, University of Ghent, Belgium.
Michael Mazen Jafar joined Evolus™ as Chief Marketing Officer in June 2018. Mr. Jafar joins the organization with nearly 15 years of commercial and executive experience building multiple market leading brands such as JUVÉDERM VOLUMA® and CoolSculpting®.
Mr. Jafar formerly served as Vice President of Marketing, U.S. Medical Aesthetics at Allergan. Prior to that, he led the assessment and integration of ZELTIQ® along with the strategic marketing for Allergan’s aesthetic portfolio of brands, including Botox® Cosmetic, JUVÉDERM® Collection, KYBELLA®, Natrelle®.
Mr. Jafar is a board member of the Irvine Public School Foundation, an Orange County based philanthropic organization. He holds an MBA from University of Southern California and a B.A. in International Finance and Supply Chain from the University of San Diego.
Brett Kopelan was initiated into the world of rare diseases eleven years ago when his daughter was born with a severe form of recessive dystrophic epidermolysis bullosa (RDEB). Shortly after her birth, Brett was elected to the board of directors of the Dystrophic Epidermolysis Bullosa Research Association of America (debra of America), the only national not-for-profit providing all-inclusive support to the EB community. Upon returning to New York City after his daughter was the 8th child in the world to undergo a stem cell transplant in hopes of treating her RDEB at the University of Minnesota, he became the Executive Director of debra of America. Prior to his rare disease work, Brett was an accomplished entrepreneur, starting three different companies raising more than $30 million in venture financing, where he led business development and marketing. He has a graduate degree from Columbia University and an undergraduate degree from New York University.
Brett currently serves as President of the board of directors of Debra International (a consortium of 55 nongovernmental organizations dedicated to curing EB), sits on the board of directors of the Alliance for Regenerative Medicine Foundation, and serves as Vice President and Secretary on a 50-year-old financial services firm’s board of directors. Brett formerly served as both the Chairman of the board of directors, and as the Treasurer of the National Organization for Rare Disorders (NORD) and as President of the board of directors of the Coalition of Skin Diseases.
Suma Krishnan is the Founder and Chief Operating Officer at Krystal Biotech (NASDAQ: KRYS). She has over 25 years of drug development experience. Prior to Krystal she was Head of Human Therapeutic Division at Intrexon Corporation (NASDAQ:XON), where she delivered on multiple gene therapy programs from discovery to clinic. Previously she led discovery, development and approval of Vyvanse (blockbuster drug for ADHD) as Sr. VP of New River Pharmaceutical (acquired by Shire). She began her career as a discovery scientist at Janssen Pharmaceuticals. She has over 20 issued patents and over 50 publications. She has her Masters in Organic Chemistry and Masters in Business Administration.
Tim Lugo, partner, joined William Blair in 2005 and focuses on the therapeutics space. Before joining William Blair, he worked at Pacific Growth Equities as a junior analyst on a number of specialty pharmaceutical companies. Mr. Lugo was named No. 1 stock picker and No. 3 earnings estimator in the 2016 Thomson Reuters Analyst Awards for his coverage of biotechnology. Mr. Lugo has a B.A. in molecular and cellular biology (with an emphasis in genetics) and a B.A. in economics, both from the University of California, Berkeley.
Peter Marinkovich has been dedicated to the study of epidermolysis bullosa his entire career. During his research training, he studied under Dr. Robert Burgeson, who discovered type VII collagen, the deficient protein in dystrophic EB. With Dr. Burgeson, Dr. Marinkovich helped to discover and characterize laminin-332, the protein affected in most junctional EB patients. Dr. Marinkovich initially developed his clinical expertise in EB while serving as an attending member of the national EB registry, along with Drs Eugene Bauer and Joseph McGuire during the 1990’s. Since 1995, Dr. Marinkovich has directed the Bullous Disease Clinic at Stanford University. He is also a longstanding member of the EB classification consensus group and has authored over 100 peer reviewed articles on basic and clinical aspects of basement membrane zone biology and blistering diseases. He writes the chapters on epidermolysis bullosa for Fitzpatrick’s Dermatology in General Medicine, WebMD and E-medicine. Dr. Marinkovich had led an NIH sponsored basic research laboratory for many years focusing on epidermolysis bullosa and basement membrane zone biology. Currently his laboratory and clinical research teams are engaged in a number of molecular gene and protein therapy studies in junctional and dystrophic epidermolysis bullosa.
Mr. Maslowski serves as Fibrocell’s President and Chief Executive Officer. Prior to that, he was Senior Vice President of Scientific Affairs, with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations. Prior to joining Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals, Inc. (now Pfizer, Inc.), eventually serving as Quality Assurance Manager. Prior to joining Wyeth, Mr. Maslowski held various positions with Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from the Ursinus College and an M.S. in Biology from Villanova University.
Raymond A. Miller is a partner and vice chair of the Health Sciences Department of Pepper Hamilton LLP, resident in the Pittsburgh office. A registered patent attorney, Mr. Miller focuses his practice on identifying, protecting, securing and maximizing the value of clients’ intellectual property. Mr. Miller’s clients include universities, research institutes and businesses ranging from idea stage through Fortune 500 companies, as well as other organizations and individuals involved in basic research and technology transfer. He has represented Ivy League universities, research organizations, pharmaceutical companies, biotechnology companies, consumer products companies, manufacturing companies, computer software developers and R&D contractors. His practice includes both prosecution and transactional IP, including acquiring and licensing patents, trademarks, copyrights and trade secrets, as well as litigation.
Mr. Miller's practice includes an array of chemical, medical, pharmaceutical, mechanical, environmental and business method fields. While he is particularly adept at handling technologies in the life sciences, he also is proficient in areas of material sciences, metallurgy, thin-film technology, specialty chemicals, polymer chemistry, nanotechnology and cosmetics.
Mr. Miller is a Chambers USA recognized practitioner; recommended in IAM Patent 1000, a guide to the world's leading patent professionals; named an Acritas Star 2018-19; and is listed in The Best Lawyers in America. Mr. Miller is a member of the American Association for the Advancement of Science, the Association of University Technology Managers, Inc. and the American Intellectual Property Law Association. He has published numerous peer-reviewed articles in academic and scientific journals.
David Moatazedi joined Evolus as President and Chief Executive Officer in May 2018. Mr. Moatazedi formerly served as Senior Vice President of U.S. Medical Aesthetics at Allergan™, leading the entire aesthetic portfolio of brands including Botox® Cosmetic, JUVEDERM® Collection, CoolSculpting®, KYBELLA®, SkinMedica®, Latisse®, Natrelle® and Alloderm®.
Mr. Moatazedi has nearly twenty years of commercial and executive experience building multiple market leading brands. David also led several acquisitions for Allergan, including LifeCell™ for $2.9B and ZELTIQ® Aesthetics for $2.5B.
Prior to Mr. Moatazedi’s thirteen years at Allergan he spent six years at Novartis Pharmaceuticals. He holds an MBA in Marketing from Pepperdine University and a B.A. in Chemistry from California State University, Long Beach.
Sanuj K. Ravindran, M.D. is President and CEO of PellePharm. Dr. Ravindran also serves on the PellePharm Board of Directors, and is CEO-in-Residence with BridgeBio, PellePharm's parent company.
Dr. Ravindran has more than 15 years of strategic and operational biopharma experience. Previously, he was chief business officer at aTyr Pharma (“LIFE”), a clinical stage rare disease-focused biotechnology company, where he led corporate strategy, financial strategy, business development, and investor relations. Prior to that, Dr. Ravindran was senior vice president of corporate development for The Medicines Company (“MDCO”), where he worked to execute multiple transactions totaling more than $2 billion in potential aggregate value. Previously a practicing physician, Dr. Ravindran began his industry career as a venture capitalist for 10 years with Burrill & Company, Radius Ventures, and Asian Healthcare Fund.
Dr. Ravindran is trained in Internal Medicine and completed his residency training at Thomas Jefferson University Hospital. Dr. Ravindran received his B.A. from Northwestern University, his M.D. from Jefferson Medical College and his MBA from the Kellogg School of Management.
João Siffert, MD, joined Abeona as Head of Research and Development and Chief Medical Officer in 2018, bringing 30 years of combined experience in the biopharmaceutical industry, clinical care, and academia. In February 2019, he was appointed Chief Executive Officer after serving in the role on an interim basis from November 2018. In February 2019, he was also appointed to the Board of Directors. Dr. Siffert has successfully led multiple drug development programs from pre-clinical to regulatory approvals and commercial launches in the U.S. and Europe and has held several scientific leadership positions in biotech and pharma, including programs in gene therapy.
In 2017, Dr. Siffert was appointed to the Board of Directors of gene therapy developer AveXis Inc., which was subsequently acquired by Novartis. Dr. Siffert began his career in industry at Pfizer, where he held medical roles of increasing responsibility from 2002 to 2005. He served as Chief Medical Officer of Avera Pharmaceuticals from 2005 to 2007, before holding the same position at Ceregene from 2007 to 2011, where he was responsible for clinical development of adeno-associated viral (AAV2)-based gene therapies for Parkinson's and Alzheimer's diseases. Dr. Siffert also led the R&D, medical, regulatory, compliance, manufacturing and quality organizations at Avanir Pharmaceuticals from 2011 to 2016. Most recently, he was the Chief Scientific and Medical Officer for Nestle Health Science, where he led translational research, clinical development and operations, regulatory, medical affairs, and health economics. Before joining industry, Dr. Siffert spent seven years in academic practice as a neuro-oncologist.
Dr. Siffert earned his M.D. from the University of São Paulo, Brazil, as well as an M.B.A. from Columbia University. He completed medical residencies in pediatrics at New York University (NYU) School of Medicine and in neurology at Harvard Medical School, followed by a fellowship in neuro-oncology at NYU. The American Board of Neurology and Psychiatry certified Dr. Siffert in 1996.
Thorsten Thormann is Vice President of Research in LEO Pharma, a function that builds and maintains a strong R&D project pipeline. Thorsten has over 20 years of experience within biomedicine and drug research and he and his team has over the past years brought a number of molecules from research and into clinical testing. This has resulted in two marketed products and several of programs currently in clinical development.
Prior to being Vice President of Research, Thorsten has over the years held a number of leadership positions within LEO Pharma aiming to build translational drug discovery platforms in dermatology as well as refocusing the early formulation and CMC to build a platform for product improvements based on usability and patient driven innovation.
Additionally Thorsten is currently responsible for building the LEO Pharma’s pipeline and organizational unit within rare skin diseases.
Thorsten Thormann has a scientific background with a MSc in Chemistry and a PhD in Protein Biology.
Ted White has served as President and Chief Executive Officer of Verrica Pharmaceuticals since December 2017 and as a member of the board of directors since May 2018. Previously, from January 2011 to September 2017, Mr. White was the President and General Manager at Almirall, a global pharmaceutical company based in Barcelona, Spain with a focus on medical dermatology, the parent company of Aqua Pharmaceuticals. Prior to Aqua Pharmaceuticals, Mr. White was at Novartis from 1989 to 2010, where he served in a number of leadership roles, most recently as a Managing Director. Mr. White holds a M.B.A. from St. Joseph’s University and a B.A. in General Arts from Villanova University.
Frederick C. Beddingfield III is founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. He started Sienna in 2016 and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he led the development of global leading brands in medical dermatology and aesthetics including Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. He has led multiple successful FDA advisor committees.
Since completing his training, Frederick has always maintained a clinical and teaching practice at UCLA where he is an Associate Clinical Professor. He is a board-certified dermatologist and emergency medicine physician and a fellowship trained dermatologic surgeon. Frederick completed his medical degree at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder.
John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $2B+ in assets under management.
William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.
Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of EdWiser, Inc. (now known as Zoomi, Inc.), is currently a member of the board of directors for Brickell Biotech, Inc., and serves on the Advisory Council for the Keller Center for Innovation Engineering Education at Princeton University.
Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.
Dr. Walker co-founded Aclaris Therapeutics, Inc. and has served as its President and CEO and a member of the board of directors since 2012. He is a board-certified dermatologist and serial entrepreneur with over 20 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson. Dr. Walker co-founded NeXeption LLC, a biopharmaceutical assets management company, in 2012. He co-founded and served as president and CEO and a member of the board of directors of Vicept Therapeutics Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan in 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics Inc., a specialty dermatology company, where he served as chief medical officer (acquired by Dr. Reddy's Laboratories Ltd.); and Cutix Inc., a commercial dermatology company. He also co-founded and continues to serve on the board of directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is on the board of directors of Aldeyra Therapeutics Inc., a publicly held biotechnology company, as well as Life Sciences Pennsylvania and several private companies. In 2016, Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award and the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology. He received a Bachelor of Arts in biology from Lehigh University, a Master of Business Administration from The Wharton School, University of Pennsylvania, and a Doctor of Osteopathic Medicine from the Philadelphia College of Osteopathic Medicine.
Albert Cha, MD, PhD. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), BioHaven Pharmaceuticals (NYSE: BHVN), KalVista Pharmaceuticals (NASDAQ: KALV), Menlo Therapeutics (NASDAQ: MNLO).
He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.
The Dermatology Summit utilizes a conference app for meeting materials and networking appointments, available on both Apple and Android devices for all registered attendees.
This app will also serve as our networking portal. Upon logging into the app, you will be able to network with other attendees and set up meetings in our 1:1 conference networking space.
Our app will launch in December, and you will receive an email at that time with download instructions.
Palace Hotel, San Francisco
2 New Montgomery Street,
San Francisco, CA 94105
The current program agenda can be found here.
Conference registration includes:
If you are interested in a sponsorship opportunity, please contact Rhonda Ware at firstname.lastname@example.org, for the sponsorship overview and level pricing.
All deliverables for confirmed speakers can be found here.
Our app will launch in December, and you will receive an email at that time with download instructions to network with other conference attendees and set up 1:1 meetings in our dedicated networking space.
There are several hotels within a short distance from the Palace Hotel, where the Dermatology Summit will take place. Please reference the list of hotels below for booking your own hotel room. The Dermatology Summit does not have contracted rates with these hotels.
|Palace Hotel||2 New Montgomery Street||415-512-1111|
|Grand Hyatt San Francisco||345 Stockton Street||415-398-1234|
|Sir Francis Drake||450 Powell Street||415-392-7755|
|Westin St. Francis||335 Powell Street||800-937-8461|
|JW Marriott||510 Mason Street||415-771-8600|
|Stanford Court Hotel||905 California Street||415-989-3500|
|Prescott, A Kimpton Hotel||545 Post Street||415-563-0303|
|Hilton San Francisco Union Square||333 O'Farrell Street||415-771-1400|
|Ritz-Carlton||600 Stockton Street||415-296-7465|
|InterContinental Mark Hopkins||999 California Street||415-392-3434|
|The Clift Hotel||495 Geary Street||415-775-4700|
|Serrano Hotel||405 Taylor Street||415-885-2500|
|Marriott Union Square||480 Sutter Street||415-398-8900|
Attire is business casual. Feel free to be comfortable in slacks, polo shirts, blazers, blouses and most importantly, comfortable shoes. We do recommend you dress in layers as temperatures in meeting rooms can vary.
After your sponsorship has been processed, you will receive an email with a unique code and instructions to register online. We encourage all complimentary and discounted registrations to be completed by December 11, 2019. If you have not yet received the email, please contact us at email@example.com.
Requests for registration fee cancellations for the conference must be received on or before December 6, 2019 by 3pm Eastern Time. At the discretion of the conference organizers, a refund via the method of original payment, minus a $125 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on December 6, 2019. Written notice of your cancellation should be sent to firstname.lastname@example.org with a copy to email@example.com.
No damages or refunds shall be due for a failure of performance by the occurrence of any contingency beyond the reasonable control of AID or Eclipse Meeting Productions. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, failure or delay in transportation, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, interruptions or failure of the Internet or third-party network connections, or acts beyond the reasonable control of the responsible parties making the Event impossible to hold.
Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.